Source: Semafor
Big Pharma’s largest commitment to AI-native drug discovery signals that generative AI has crossed from experimental lab tool to business-critical infrastructure in pharmaceutical R&D. The deal with Insilico Medicine—a company that has already moved 28 AI-designed candidates into development—suggests the bottleneck in drug discovery is shifting from scientific feasibility to manufacturing, regulatory approval, and clinical validation. This represents a structural shift in how pharmaceutical value gets created: companies that can integrate AI pipelines at scale may compress drug development timelines by years, fundamentally reshaping competitive advantage in an industry built on patent exclusivity windows.